来源:医学新视点
不少研究已经提供有力证据,表明新型冠状病毒(SARS-CoV-2)通过血管紧张素转换酶2(ACE2)这一受体入侵细胞。随之而来的,是一些担忧降压药物潜在风险的声音。
截图来源:ESC官网
声明指出,有关ACE抑制剂或ARB与COVID-19相关的安全性,尚无合理的科学依据或证据支持相关推测。有来自动物研究的证据表明,这些药物在COVID-19感染患者中可能对严重的肺部并发症具有保护作用,但迄今为止尚无人类数据。ESC高血压委员会尤其强调,在COVID-19大流行的背景下,缺乏任何证据支持ACE抑制剂和ARB的有害影响。因此,“强烈建议医生和患者继续常规的降压治疗,目前没有临床或科学证据表明需要考虑COVID-19感染风险而中止ACE抑制剂或ARB的治疗。”
参考资料
[1] Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. Retrieved Mar 17, 2020, from https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang
[2] ESC Says Continue Hypertension Meds Despite COVID-19 Concern. Retrieved Mar 17, 2020, from https://www.medscape.com/viewarticle/926838
[3] Scientists Seek Answers to Hypertension–COVID-19 Link. Retrieved Mar 17, 2020, from https://www.medscape.com/viewarticle/926665
[4] Ying-Ying Zheng, et al., (2020). COVID-19 and the cardiovascular system. Nat Rev Cardiol, DOI: 10.1038/s41569-020-0360-5
[5] Lei Fang, et al., (2020). Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respiratory Medicine, DOI:10.1016/S2213-2600(20)30116-8
来源:HealthHorizon 医学新视点
原文链接:http://mp.weixin.qq.com/s?__biz=MzAxOTU2OTU4MQ==&mid=2649914415&idx=2&sn=d51b79190b8562eb4fd4341875f1f14d&chksm=83c3d2edb4b45bfb0d40b590f53deadd224be5bded304faaaed06acb75375fa1defc2862a510&scene=27#wechat_redirect
版权声明:除非特别注明,本站所载内容来源于互联网、微信公众号等公开渠道,不代表本站观点,仅供参考、交流、公益传播之目的。转载的稿件版权归原作者或机构所有,如有侵权,请联系删除。
电话:(010)86409582
邮箱:kejie@scimall.org.cn